About Syros Pharmaceuticals
Syros Pharmaceuticals is a company based in Watertown (United States) founded in 2012.. Syros Pharmaceuticals has raised $124.4 million across 7 funding rounds from investors including Fidelity Investments, TD Securities and Flagship Pioneering. Syros Pharmaceuticals operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Watertown, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Syros Pharmaceuticals, Inc.
-
Annual Revenue
$9.94 M-33.23as on Dec 31, 2023
-
Net Profit
$-164.57 M-73.87as on Dec 31, 2023
-
EBITDA
$-124.25 M-0.69as on Dec 31, 2023
-
Total Equity Funding
$124.4 M (USD)
in 7 rounds
-
Latest Funding Round
$130 M (USD), Post-IPO
Sep 16, 2022
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Syros Pharmaceuticals
Syros Pharmaceuticals is a publicly listed company on the OTC with ticker symbol SYRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of Syros Pharmaceuticals
Syros Pharmaceuticals has successfully raised a total of $124.4M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $130 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $130.0M
-
First Round
First Round
(15 Aug 2012)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Post-IPO - Syros Pharmaceuticals | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - Syros Pharmaceuticals | Valuation |
investors |
|
| Feb, 2018 | Amount | Post-IPO - Syros Pharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Syros Pharmaceuticals
Syros Pharmaceuticals has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, TD Securities and Flagship Pioneering. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Syros Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Syros Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Syros Pharmaceuticals Comparisons
Competitors of Syros Pharmaceuticals
Syros Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Syros Pharmaceuticals
Frequently Asked Questions about Syros Pharmaceuticals
When was Syros Pharmaceuticals founded?
Syros Pharmaceuticals was founded in 2012.
Where is Syros Pharmaceuticals located?
Syros Pharmaceuticals is headquartered in Watertown, United States.
Who is the current CEO of Syros Pharmaceuticals?
Conley Chee is the current CEO of Syros Pharmaceuticals.
Is Syros Pharmaceuticals a funded company?
Syros Pharmaceuticals is a funded company, having raised a total of $124.4M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $11.38M, raised on Aug 15, 2012.
What is the annual revenue of Syros Pharmaceuticals?
Annual revenue of Syros Pharmaceuticals is $9.94M as on Dec 31, 2023.
What does Syros Pharmaceuticals do?
Syros Pharmaceuticals was founded in 2012 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule therapeutics are developed to address cancer and genetic diseases. The lead program, SY-1425, targets relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome as a selective RARa agonist. Additionally, SY-1365 serves as a selective CDK7 inhibitor for acute leukemia treatment.
Who are the top competitors of Syros Pharmaceuticals?
Syros Pharmaceuticals's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Is Syros Pharmaceuticals publicly traded?
Yes, Syros Pharmaceuticals is publicly traded on OTC under the ticker symbol SYRS.
Who are Syros Pharmaceuticals's investors?
Syros Pharmaceuticals has 21 investors. Key investors include Fidelity Investments, TD Securities, Flagship Pioneering, Orbimed, and Arch Venture Partners.
What is Syros Pharmaceuticals's ticker symbol?
The ticker symbol of Syros Pharmaceuticals is SYRS on OTC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.